Claritas Pharmaceuticals IncTSXV:CLAS.HView on Over The Counter Market
- LAST PRICE0.0250
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close--- / 0.0250
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Claritas Pharmaceuticals Inc | 974.6K | -0.3x | --- |
Vaxil Bio Ltd | 1.4M | -12.5x | --- |
MYND Life Sciences Inc | 1.2M | -4.2x | --- |
Restart Life Sciences Corp | 1.2M | -1.9x | --- |
Zenith Capital Corp | 786.8K | -1.3x | --- |
GeneTether Therapeutics Inc | 775.8K | -1.0x | --- |
Company Information
Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.
Contact Information
- Headquarters
- 4040 Civic Center Drive, Suite 200SAN RAFAEL, CA, United States 94903
- Phone
- 416-362-4441
- Fax
- 403-266-8647
Executives
- Chairman of the Board, President, Chief Executive Officer
- Robert Farrell
- Interim Chief Financial Officer, Treasurer, Secretary
- Victoria Rudman
- Independent Director
- Salvatore Cuzzocrea
- Independent Director
- Perenlei Enkhbaatar
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $974.6K |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 37.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-0.09 |
Book Value | $0.08 |
P/E Ratio | -0.3x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
